NATTO: 4th Quarter and Full Year 2016 earnings release

Please find attached the 4th Quarter and Full Year 2016 Earnings Release. 

Highlights for the 4th Quarter and for the Full Year are;  

4th Quarter 2016
  • Revenue rose by 44 % to NOK 15,9 million
  • Gross Margin for the period was 46 %, up from 31 % in Q4’15
  • Positive EBITDA of NOK 0,2 million
  • Profit after tax was NOK 0,6 million
Full Year 2016
  • Revenue rose by 66 % to NOK 52,5 million
  • Gross Margin for the year was 45 %
  • EBITDA coming in at NOK -9,1 million
  • Loss after tax was NOK -18,2 million  

A presentation will be held via webcast by CEO Daniel H. Rosenbaum and CFO Kjetil Ramsøy at 10 am CET, Wednesday 7th February 2017, followed by a Q&A session directly thereafter.

Please follow the below link to join the webcast ;

http://webtv.hegnar.no/presentation.php?webcastId=44466805  


For more information, please contact:

Kjetil Ramsøy

CFO, NattoPharma

E-mail: kjetil.ramsoy@nattopharma.com

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

Tags:

About Us

NattoPharma, the world leader in Vitamin K2 Research and Development, has invested millions of dollars in in-vitro, in-vivo, and clinical studies to document the effects of MenaQ7® Vitamin K2 as MK-7. This commitment has created the only patented and clinically validated K2 on the market. After establishing the first commercial Vitamin K2 with its flagship brand, MenaQ7®, NattoPharma has consistently answered and met market needs through the development of new production technologies:• In 2012, the company introduced MenaQ7® Crystals, which represented an important breakthrough in the new generation of Vitamin K2 products, producing the purest natural MK-7 available.• In 2014, NattoPharma introduced the only all-trans nature-identical synthesized Vitamin K2, MenaQ7® PURE. Not only did the company succeed in changing the market with MenaQ7® PURE – offering a high-quality, competitively priced ingredient – but its efforts were rewarded with the NutrAward for Best Functional Ingredient at Natural Products West/engredea 2015. Vitamin K2 is essential for the body to utilize calcium to build healthy, strong bones and to inhibit calcium deposits in the arteries. Published clinical studies have demonstrated the high bioavailability and proof of efficacy for Nattopharma’s all-trans MK-7 products in healthy and diseased populations, for bone and cardiovascular health. NattoPharma continues to build its competitive advantage through focuson IPR and has patents both granted and pending related to relevant healthbenefits and market segments, creating extra value for its customers. And NattoPharma staff consists of professionals people with longstanding experience in medical and biochemical research as well as pharmaceutical and food supplement development. By understanding and controlling the chemistry, NattoPharma provides the market all-trans MK-7 products, while our sales and marketing team has extensive knowledge of international market demands with which it supports our partners.